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L I N K TO O R I G I N A L A RT I C L E L I N K TO I N I T I A L C O R R E S P O N D E N C E
In their recent correspondence related to an interview discussing the Voluntary Harmoni zation Procedure (VHP) for the assessment of multinational clinical trials in the European Union (EU) ( The main advantage of the VHP is that the assessment of a multinational clinical trial application (MCTA) by the relevant member states is done in a coordinated way.
The applicant has to provide electronically to a single point -the VHP coordinatoronly general documents such as the protocol, investigator's brochure and investigational medicinal product dossier. The coordinated assessment procedure by the member states themselves is divided into three phases. VHP phase 1 is the validation of the unique dossier. VHP phase 2 starts with the scien tific assessment of the MCTA by the chosen member states, which is performed within 30 days. Subsequently, the MCTA receives a positive opinion if there are no grounds for nonacceptance; if there are such grounds, the applicant receives a single consolidated list of these, which have to be addressed within 10 days. The answers are assessed by the member states, and after another 20 days a common final position is issued (that is, positive, negative or positive with conditions). For other than positive decisions, the reasons are given to the sponsor. VHP phase 3 is the national step after a positive opinion, in which only formal documents are needed to get the national authorization within 10 days. So, for the sponsor as well as for the member states, the VHP guarantees short, reliable timelines, in which the general documents are scientifi cally assessed, and no further memberstate specific modifications of general documents are necessary. With the implementation of VHP version 2 from March 2010, a few new features have also been introduced 4 . For example, all clinical trials with three mem ber states can be applied for, assessment is coordinated by a leading member state, and application for substantial amendments is also possible.
The Currently, Poland cannot participate owing to lack of a legal basis. The average number of member states selected for a VHP and finally participating in the assessment is 6, with a range from 2 to 14 per application.
With version 2 of the VHP guidance, one of the biggest improvements was the imple mentation of an internal leading member state, whose task is to consolidate the list of questions of the single member state arising during assessment, thereby avoiding redun dancy of questions. This resulted in an average reduction of initial questions by around 50% before they were sent to the applicant.
The main benefit of the VHP is the reduc tion in time for the approval of the MCTA, which is demonstrated by the data in FIG. 1 If only a single participating member state required additional changes to be able to approve the national application. maximum of 60 days (which also comprises the 10 days of sponsor's time to resolve grounds for nonacceptance) preceded by a 5day valida tion. Subsequent national approval is achieved within 10 days, after the applicant has had 20 days to submit a valid application to the national competent authorities (NCAs). The experience with the VHP so far is that time lines for the VHP are met or even reduced. In the first year following the introduction of the VHP the national step was timeconsuming for both the sponsor and the NCAs, but in the third year 10% less time than scheduled was needed for an MCTA approval (FIG. 1) .
Further improvements for the VHP came into force in September 2011. First, the assess ment of an MCTA has been further improved. The leading member state is now replaced by a referenceNCA with the possibility to introduce a coreference NCA, depending on the nature of the investigational medicinal product. The other participating NCAs receive the preliminary assessment report, and can decide on this basis whether they agree or whether they have additional grounds for nonacceptance to produce a more stringent list of such grounds and use resources more efficiently. The second alteration is the pos sibility to have a second round of a VHP to add additional member states in an already approved VHP. Timelines for the second round are, in principle, the same as in the first round. However, as the assessment report from the first round is adopted, assessment by the new member states might speed up and approval might be quicker. Overall, these improvements should save further time for applicants.
